RxDoctor Payments Data

Lyden Odukwu, MD

Family Medicine · Midland, TXNPI 1043204035

Payments from drug & device makers

$13,418in general payments, 2019–2025

Across 830 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Amgen$2K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • Astellas Pharma US Inc$571
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$13,32099%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,418 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$80,829
Medicare patients
186
Services billed
884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$94,212
RybelsusSemaglutide40$61,836
MounjaroTirzepatide51$53,184
JardianceEmpagliflozin40$42,284
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog32$38,901
Tresiba Flextouch U-200Insulin Degludec26$34,045
FarxigaDapagliflozin Propanediol37$33,063
EliquisApixaban31$31,741
JanuviaSitagliptin Phosphate22$27,176
GlyxambiEmpagliflozin/Linagliptin19$26,196
XareltoRivaroxaban16$25,013
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$22,477
JanumetSitagliptin Phos/Metformin Hcl17$15,726
TrulicityDulaglutide16$15,417
QuliptaAtogepant11$11,690

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,129$156,048120 claims
Lilly USA, LLCMounjaro, Trulicity$1,317$68,60167 claims
Boehringer IngelheimJardiance, Glyxambi$531$68,48059 claims
MerckJanuvia, Janumet, Janumet Xr$247$54,31255 claims
AstraZenecaFarxiga$2,239$33,06337 claims
PfizerEliquis$560$31,74131 claims
Johnson & JohnsonXarelto$128$25,01316 claims
GSKTrelegy Ellipta$474$22,47731 claims
AbbVieQulipta$1,884$11,69011 claims
Astellas Pharma US IncMyrbetriq$571$9,68613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Midland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →